{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:14:28Z","timestamp":1778652868570,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-CD20 therapy with rituximab serves as the cornerstone of both induction and maintenance treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is designed for more potent and sustained B-cell depletion with improved tolerability. Due to the paucity of clinical evidence of obinutuzumab in AAV, we undertook this study to assess its efficacy and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twelve consecutive patients with AAV who received first obinutuzumab treatment between September 2022 and December 2024 were included in this retrospective study. Clinical and pathological data were collected at predefined time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four patients received obinutuzumab for induction therapy, and 8 for maintenance therapy. The median follow-up duration after obinutuzumab administration was 17.5 months. Among the 4 patients receiving obinutuzumab for induction therapy, one patient progressed to end-stage kidney disease after infection, while the other 3 achieved sustained remission. Among the 8 patients receiving obinutuzumab for maintenance therapy, no relapse occurred. Among all the patients, three experienced at least one severe adverse event following obinutuzumab therapy. B-cell reconstitution typically began 9\u201312 months after obinutuzumab administration, with one patient showing no reconstitution at 24 months of follow-up. Concomitant with B-cell depletion, ANCA levels gradually declined in most patients and became undetectable in half. Notably, ANCA levels continued to decrease for up to one year after obinutuzumab administration, even after B-cell reconstitution began.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Obinutuzumab was effective and well-tolerated in AAV patients, supporting its potential as an alternative anti-CD20 therapy for AAV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1787558","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:54:09Z","timestamp":1778651649000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Obinutuzumab treatment for antineutrophil cytoplasmic antibody-associated vasculitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Chen","family":"Ye","sequence":"first","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital","place":["Beijing, China"]},{"name":"Institute of Nephrology, Peking University","place":["Beijing, China"]},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China","place":["Beijing, China"]},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-ying","family":"Li","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital","place":["Beijing, China"]},{"name":"Institute of Nephrology, Peking University","place":["Beijing, China"]},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China","place":["Beijing, China"]},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-yu","family":"Han","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital","place":["Beijing, China"]},{"name":"Institute of Nephrology, Peking University","place":["Beijing, China"]},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China","place":["Beijing, China"]},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital","place":["Beijing, China"]},{"name":"Institute of Nephrology, Peking University","place":["Beijing, China"]},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China","place":["Beijing, China"]},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Peking University First Hospital","place":["Beijing, China"]},{"name":"Institute of Nephrology, Peking University","place":["Beijing, China"]},{"name":"Key Laboratory of Renal Disease, Ministry of Health of China","place":["Beijing, China"]},{"name":"Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education","place":["Beijing, China"]},{"name":"Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences","place":["Beijing, China"]},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: current and emerging treatment options","volume":"14","author":"McClure","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41584-025-01266-1","article-title":"Advances in the treatment of ANCA-associated vasculitis","volume":"21","author":"Trivioli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.01.022","article-title":"Obinutuzumab in rituximab-intolerant antineutrophil cytoplasmic antibody-associated vasculitis patients","volume":"10","author":"van Leeuwen","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.04.026","article-title":"Obinutuzumab for relapsing myeloperoxidase-antineutrophil cytoplasmic autoantibody\u2013associated glomerulonephritis","volume":"10","author":"Cammarata","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1624234","article-title":"Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199568741.003.0272","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ndt\/gfaf127","article-title":"Urinary rituximab loss and rate of treatment failure in membranous nephropathy","volume":"41","author":"Allinovi","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083277","article-title":"Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas","volume":"14","author":"McGovern","year":"2024","journal-title":"BMJ Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1787558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:54:11Z","timestamp":1778651651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1787558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1787558"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1787558","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1787558"}}